News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
NIH funding by institution for FY 2023
Photo taken from: NIH.gov webpage
Jul 11, 2023, 02:42

NIH funding by institution for FY 2023

NIH funding by institution for FY 2023
  1. Johns Hopkins U $518M
  2. UCSF $451M
  3. U Michigan $436M
  4. Penn $434M
  5. UCLA $424M
  6. Stanford $407M
  7. Mass General $406M
  8. Wash U. $404M
  9. Yale $390M
  10. Pitt $382M
  11. Columbia $362M
  12. Duke $360M
Source: Denis Wirtz / Twitter 
funding NIH OncoDaily Oncology
Special Coverage
Blog
Dec 21, 2024, 19:42
Ruben Mesa: Over 200 research staff of Atrium Health Wake Forest Baptist trained on Just Ask Increasing Diversity in Cancer Clinical Trials
Blog
Dec 21, 2024, 19:39
Kyaw Thein: Investigational Treatments for Thyroid and Head and Neck Cancers
Blog
Dec 21, 2024, 19:25
Hesham ElGhazaly: From an academic institution into a globally recognized hub for healthcare, research and innovation
Blog
Dec 21, 2024, 19:21
Douglas Flora: The 19 Words I’m Learning to Embrace as a Leader in 2025
Blog
Dec 21, 2024, 19:19
Registration and abstract submission open for the PTCOG63 - SIOP Europe
Blog
Dec 21, 2024, 19:18
The Institute of Cancer Research's annual report for 2023-2024
Blog
Dec 21, 2024, 19:14
Pembrolizumab plus chemotherapy with or without bevacizumab for metastatic cervical cancer
Blog
Dec 21, 2024, 19:12
The International Cancer Control Partnership's latest global review of NCCPs is out now - NCI Center for Global Health
Blog
Dec 21, 2024, 18:59
Nominations for the SIOP Europe Lifetime Achievement are open
Blog
Dec 21, 2024, 18:57
Petra Ibum Adjah: Get your last self breast exams before the festivities begin
Blog
Dec 21, 2024, 18:54
Introducing Innovation at Your Fingertips - Total Health | Oncology
Insight
Dec 21, 2024, 18:46
Marengo Initiated Phase 2 Trial of Invikafusp Alfa for PD-1 Resistant Tumors, Expands to Europe